Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy

Noriyuki Akutsu, Shigeru Sasaki, Hideyasu Takagi, Masayo Motoya, Masahiro Shitani, Mai Igarashi, Daisuke Hirayama, Hideki Wakasugi, Hiroyuki Yamamoto, Hiroyuki Kaneto, Kazuhiko Yonezawa, Atsushi Yawata, Takeya Adachi, Yasuo Hamamoto, Yasuhisa Shinomura

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Sorafenib is an agent that inhibits vascular endothelial growth factor and is associated with onset or worsening of hypertension in some patients. We conducted a retrospective analysis of whether the development of hypertension during sorafenib treatment of advanced hepatocellular carcinoma could be a predictor of anti-cancer efficacy. Methods: The study included 38 patients with advanced hepatocellular carcinoma who had received sorafenib for at least 1 month between January 2010 and December 2012. A retrospective analysis of the efficacy of sorafenib was conducted by dividing the patients into two groups—a hypertension group, presenting with grade 2 or higher hypertension according to the Common Terminology Criteria for Adverse Events (CTCTE) version 4.0; and a non-hypertension group, which included all other patients. This study evaluated the occurrence of hypertension within 2 weeks of initiation of therapy in order to avoid any treatment duration bias. Images were evaluated using the modified Response Evaluation Criteria in Solid Tumors. The response rate, time to progression, and overall survival were assessed. Results: Twenty-two patients (58 %) developed grade 2 or higher hypertension within 2 weeks of initiation of therapy. The response rate was significantly higher in the hypertension group. Median time to progression was 153 days in the hypertension group versus 50.5 days in the non-hypertension group, which was significantly longer in the hypertension group. Moreover, median overall survival was 1,329 days in the hypertension group versus 302 days in the non-hypertension group, which was significantly longer in the hypertension group. Conclusions: Hypertension within 2 weeks of initiation of therapy may be a predictor of the anti-cancer efficacy of sorafenib when used for the treatment of advanced hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)105-110
Number of pages6
JournalInternational Journal of Clinical Oncology
Volume20
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Hepatocellular Carcinoma
Hypertension
sorafenib
Therapeutics
Survival
Terminology
Vascular Endothelial Growth Factor A
Neoplasms

Keywords

  • Hepatocellular carcinoma
  • Hypertension
  • Sorafenib

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Cite this

Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. / Akutsu, Noriyuki; Sasaki, Shigeru; Takagi, Hideyasu; Motoya, Masayo; Shitani, Masahiro; Igarashi, Mai; Hirayama, Daisuke; Wakasugi, Hideki; Yamamoto, Hiroyuki; Kaneto, Hiroyuki; Yonezawa, Kazuhiko; Yawata, Atsushi; Adachi, Takeya; Hamamoto, Yasuo; Shinomura, Yasuhisa.

In: International Journal of Clinical Oncology, Vol. 20, No. 1, 01.01.2015, p. 105-110.

Research output: Contribution to journalArticle

Akutsu, N, Sasaki, S, Takagi, H, Motoya, M, Shitani, M, Igarashi, M, Hirayama, D, Wakasugi, H, Yamamoto, H, Kaneto, H, Yonezawa, K, Yawata, A, Adachi, T, Hamamoto, Y & Shinomura, Y 2015, 'Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy', International Journal of Clinical Oncology, vol. 20, no. 1, pp. 105-110. https://doi.org/10.1007/s10147-014-0691-5
Akutsu, Noriyuki ; Sasaki, Shigeru ; Takagi, Hideyasu ; Motoya, Masayo ; Shitani, Masahiro ; Igarashi, Mai ; Hirayama, Daisuke ; Wakasugi, Hideki ; Yamamoto, Hiroyuki ; Kaneto, Hiroyuki ; Yonezawa, Kazuhiko ; Yawata, Atsushi ; Adachi, Takeya ; Hamamoto, Yasuo ; Shinomura, Yasuhisa. / Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. In: International Journal of Clinical Oncology. 2015 ; Vol. 20, No. 1. pp. 105-110.
@article{48901cef9cbc425aa6a30d71eb2252cf,
title = "Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy",
abstract = "Background: Sorafenib is an agent that inhibits vascular endothelial growth factor and is associated with onset or worsening of hypertension in some patients. We conducted a retrospective analysis of whether the development of hypertension during sorafenib treatment of advanced hepatocellular carcinoma could be a predictor of anti-cancer efficacy. Methods: The study included 38 patients with advanced hepatocellular carcinoma who had received sorafenib for at least 1 month between January 2010 and December 2012. A retrospective analysis of the efficacy of sorafenib was conducted by dividing the patients into two groups—a hypertension group, presenting with grade 2 or higher hypertension according to the Common Terminology Criteria for Adverse Events (CTCTE) version 4.0; and a non-hypertension group, which included all other patients. This study evaluated the occurrence of hypertension within 2 weeks of initiation of therapy in order to avoid any treatment duration bias. Images were evaluated using the modified Response Evaluation Criteria in Solid Tumors. The response rate, time to progression, and overall survival were assessed. Results: Twenty-two patients (58 {\%}) developed grade 2 or higher hypertension within 2 weeks of initiation of therapy. The response rate was significantly higher in the hypertension group. Median time to progression was 153 days in the hypertension group versus 50.5 days in the non-hypertension group, which was significantly longer in the hypertension group. Moreover, median overall survival was 1,329 days in the hypertension group versus 302 days in the non-hypertension group, which was significantly longer in the hypertension group. Conclusions: Hypertension within 2 weeks of initiation of therapy may be a predictor of the anti-cancer efficacy of sorafenib when used for the treatment of advanced hepatocellular carcinoma.",
keywords = "Hepatocellular carcinoma, Hypertension, Sorafenib",
author = "Noriyuki Akutsu and Shigeru Sasaki and Hideyasu Takagi and Masayo Motoya and Masahiro Shitani and Mai Igarashi and Daisuke Hirayama and Hideki Wakasugi and Hiroyuki Yamamoto and Hiroyuki Kaneto and Kazuhiko Yonezawa and Atsushi Yawata and Takeya Adachi and Yasuo Hamamoto and Yasuhisa Shinomura",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s10147-014-0691-5",
language = "English",
volume = "20",
pages = "105--110",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy

AU - Akutsu, Noriyuki

AU - Sasaki, Shigeru

AU - Takagi, Hideyasu

AU - Motoya, Masayo

AU - Shitani, Masahiro

AU - Igarashi, Mai

AU - Hirayama, Daisuke

AU - Wakasugi, Hideki

AU - Yamamoto, Hiroyuki

AU - Kaneto, Hiroyuki

AU - Yonezawa, Kazuhiko

AU - Yawata, Atsushi

AU - Adachi, Takeya

AU - Hamamoto, Yasuo

AU - Shinomura, Yasuhisa

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Sorafenib is an agent that inhibits vascular endothelial growth factor and is associated with onset or worsening of hypertension in some patients. We conducted a retrospective analysis of whether the development of hypertension during sorafenib treatment of advanced hepatocellular carcinoma could be a predictor of anti-cancer efficacy. Methods: The study included 38 patients with advanced hepatocellular carcinoma who had received sorafenib for at least 1 month between January 2010 and December 2012. A retrospective analysis of the efficacy of sorafenib was conducted by dividing the patients into two groups—a hypertension group, presenting with grade 2 or higher hypertension according to the Common Terminology Criteria for Adverse Events (CTCTE) version 4.0; and a non-hypertension group, which included all other patients. This study evaluated the occurrence of hypertension within 2 weeks of initiation of therapy in order to avoid any treatment duration bias. Images were evaluated using the modified Response Evaluation Criteria in Solid Tumors. The response rate, time to progression, and overall survival were assessed. Results: Twenty-two patients (58 %) developed grade 2 or higher hypertension within 2 weeks of initiation of therapy. The response rate was significantly higher in the hypertension group. Median time to progression was 153 days in the hypertension group versus 50.5 days in the non-hypertension group, which was significantly longer in the hypertension group. Moreover, median overall survival was 1,329 days in the hypertension group versus 302 days in the non-hypertension group, which was significantly longer in the hypertension group. Conclusions: Hypertension within 2 weeks of initiation of therapy may be a predictor of the anti-cancer efficacy of sorafenib when used for the treatment of advanced hepatocellular carcinoma.

AB - Background: Sorafenib is an agent that inhibits vascular endothelial growth factor and is associated with onset or worsening of hypertension in some patients. We conducted a retrospective analysis of whether the development of hypertension during sorafenib treatment of advanced hepatocellular carcinoma could be a predictor of anti-cancer efficacy. Methods: The study included 38 patients with advanced hepatocellular carcinoma who had received sorafenib for at least 1 month between January 2010 and December 2012. A retrospective analysis of the efficacy of sorafenib was conducted by dividing the patients into two groups—a hypertension group, presenting with grade 2 or higher hypertension according to the Common Terminology Criteria for Adverse Events (CTCTE) version 4.0; and a non-hypertension group, which included all other patients. This study evaluated the occurrence of hypertension within 2 weeks of initiation of therapy in order to avoid any treatment duration bias. Images were evaluated using the modified Response Evaluation Criteria in Solid Tumors. The response rate, time to progression, and overall survival were assessed. Results: Twenty-two patients (58 %) developed grade 2 or higher hypertension within 2 weeks of initiation of therapy. The response rate was significantly higher in the hypertension group. Median time to progression was 153 days in the hypertension group versus 50.5 days in the non-hypertension group, which was significantly longer in the hypertension group. Moreover, median overall survival was 1,329 days in the hypertension group versus 302 days in the non-hypertension group, which was significantly longer in the hypertension group. Conclusions: Hypertension within 2 weeks of initiation of therapy may be a predictor of the anti-cancer efficacy of sorafenib when used for the treatment of advanced hepatocellular carcinoma.

KW - Hepatocellular carcinoma

KW - Hypertension

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=84939874793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939874793&partnerID=8YFLogxK

U2 - 10.1007/s10147-014-0691-5

DO - 10.1007/s10147-014-0691-5

M3 - Article

VL - 20

SP - 105

EP - 110

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 1

ER -